Loading...
OTCM
LOBEF
Market cap481kUSD
Jul 11, Last price  
0.00USD
1D
-90.57%
1Q
-91.07%
IPO
-96.88%
Name

Lobe Sciences Ltd

Chart & Performance

D1W1MN
P/E
P/S
4.85
EPS
Div Yield, %
Shrs. gr., 5y
72.62%
Rev. gr., 5y
-29.35%
Revenues
136k
-83.80%
0000000773,792884,83700840,534136,205
Net income
-4m
L-6.09%
-91,001-93,104-133,955-106,424-170,839-55,972-51,795-754,431-3,436,073-9,658,412-12,252,852-4,707,349-4,420,727
CFO
-462k
L-73.10%
-44,924-84,704-126,342-106,202-59,767-44,843-51,934-2,043,609-1,222,417-5,037,358-2,730,729-1,718,644-462,293
Earnings
Jul 24, 2025

Profile

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
IPO date
Jun 19, 2012
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082017‑122016‑122015‑12
Income
Revenues
136
-83.80%
841
 
Cost of revenue
2,168
4,156
4,123
Unusual Expense (Income)
NOPBT
(2,031)
(3,316)
(4,123)
NOPBT Margin
Operating Taxes
33
205
5,490
Tax Rate
NOPAT
(2,064)
(3,521)
(9,614)
Net income
(4,421)
-6.09%
(4,707)
-61.58%
(12,253)
26.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
676
753
BB yield
Debt
Debt current
641
333
Long-term debt
1,106
Deferred revenue
Other long-term liabilities
Net debt
1,509
192
(1,590)
Cash flow
Cash from operating activities
(462)
(1,719)
(2,731)
CAPEX
Cash from investing activities
1,743
Cash from financing activities
564
950
753
FCF
(2,538)
(2,184)
(7,909)
Balance
Cash
238
140
908
Long term investments
682
Excess cash
231
98
1,590
Stockholders' equity
(3,114)
(8,060)
446
Invested Capital
1,747
8,232
ROIC
ROCE
148.55%
EV
Common stock shares outstanding
122,134
104,351
37,862
Price
Market cap
EV
EBITDA
(1,947)
(3,272)
(4,113)
EV/EBITDA
Interest
187
39
Interest/NOPBT